

## Summary of Utilization Management (UM) Program Changes

**May 2020**

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Actemra</i>	tocilizumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of a disease-modifying anti-rheumatic drug</li> <li>• Trial of two from the following: Cimzia, Humira, Rinvoq, Simponi/Simponia Aria, Xeljanz/Xeljanz XR</li> </ul> <p>Systemic Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of a nonsteroidal anti-inflammatory drug or systemic glucocorticoid</li> </ul> <p>Polyarticular Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of leflunomide or methotrexate</li> <li>• Trial of Humira</li> </ul> <p>Giant Cell Arteritis</p> <ul style="list-style-type: none"> <li>• Trial of a glucocorticoid</li> </ul> <p>Cytokine Release Syndrome (CRS) Risk due to CAR T-Cell Therapy</p> <ul style="list-style-type: none"> <li>• Receiving or will receive CAR T-cell immunotherapy</li> <li>• Prescribed by or with an oncologist or hematologist</li> </ul>	Update	7/01/2020
<i>Cimzia</i>	certolizumab pegol	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of a disease-modifying anti-rheumatic drug</li> </ul> <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> <li>• Active disease</li> <li>• Trial of 2 nonsteroidal anti-inflammatory drugs</li> </ul> <p>Non-radiographic axial spondylitis</p> <ul style="list-style-type: none"> <li>• Objective signs of inflammation (lab test or MRI)</li> <li>• Trial of 2 nonsteroidal anti-inflammatory drugs</li> <li>• Prescribed by or with a rheumatologist</li> </ul> <p>Crohn's Disease</p> <ul style="list-style-type: none"> <li>• Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or methotrexate</li> </ul>	Update	7/01/2020

<i>Cosentyx</i>	secukinumab	<p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> <li>• Active disease</li> <li>• Trial of 2 nonsteroidal anti-inflammatory drugs</li> <li>• Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria</li> <li>• Trial of Taltz</li> </ul> <p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>• Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya</li> </ul> <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara</li> <li>• Trial of Orencia or Xeljanz/Xeljanz XR</li> <li>• Trial of Taltz</li> </ul>	Update	7/01/2020
<i>Enbrel</i>	etanercept	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of a disease-modifying anti-rheumatic drug</li> <li>• Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR</li> <li>• Trial of Actemra and Orencia</li> </ul> <p>Polyarticular Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of leflunomide or methotrexate</li> <li>• Trial of Humira, Actemra, and Orencia</li> </ul> <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>• Trial of three from the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara</li> <li>• Trial of two of the following: Taltz, Orencia, Xeljanz/Xeljanz XR</li> </ul> <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> <li>• Active disease</li> <li>• Trial of 2 nonsteroidal anti-inflammatory drugs</li> <li>• Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria</li> <li>• Trial of Taltz</li> </ul> <p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>• For ages 18 and older: Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya</li> <li>• Trial of Taltz</li> </ul>	Update	7/01/2020

		<ul style="list-style-type: none"> <li>For ages 12-17: Trial of Stelara</li> </ul>		
<i>Entyvio</i>	vedolizumab	<p>Crohn's Disease</p> <ul style="list-style-type: none"> <li>Trial of two from the following: Humira, infliximab, Cimzia, Stelara</li> </ul> <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> <li>Trial of two from the following: Simponi, Humira, infliximab, Stelara</li> </ul>	Update	7/01/2020
<i>Humira</i>	adalimumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>Trial of a disease-modifying anti-rheumatic drug</li> </ul> <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> <li>Trial of 2 nonsteroidal anti-inflammatory drugs</li> </ul> <p>Polyarticular Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> <li>Trial of leflunomide and methotrexate</li> </ul> <p>Crohn's Disease</p> <ul style="list-style-type: none"> <li>Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosaliclylate</li> </ul> <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> <li>Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosaliclylate</li> </ul>	Update	7/01/2020
<i>Ilumya</i>	tildrakizumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya</li> <li>Trial of Taltz</li> </ul>	Update	07/01/2020
<i>Kevzara</i>	sarilumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>Trial of a disease-modifying anti-rheumatic drug</li> <li>Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR</li> <li>Trial of Actemra and Orencia</li> </ul>	Update	7/01/2020
<i>Kineret</i>	anakinra	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>Trial of a disease-modifying anti-rheumatic drug</li> <li>Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR</li> <li>Trial of Actemra and Orencia</li> </ul> <p>Neonatal-Onset Multisystem Inflammatory Disease (NOMID)</p> <ul style="list-style-type: none"> <li>Diagnosis confirmed by specific genetic mutation</li> </ul>	Update	7/01/2020

		<ul style="list-style-type: none"> <li>Any two of the following symptoms: urticaria-like rash; cold/stress triggered episodes; sensorineural hearing loss; musculoskeletal symptoms; chronic aseptic meningitis; skeletal abnormalities</li> <li>Elevated acute phase reactants (lab test)</li> <li>Prescribed by or with an allergist/immunologist, rheumatologist, or pediatrician</li> </ul> <p>Systemic Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> <li>Prescribed by or with a rheumatologist</li> <li>Trial of a nonsteroidal anti-inflammatory drug or systemic glucocorticoid</li> </ul>		
<i>Olumiant</i>	baricitinib	<p>Rheumatoid arthritis</p> <ul style="list-style-type: none"> <li>Moderate to severe disease</li> <li>Trial of a disease-modifying anti-rheumatic drug</li> <li>Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR</li> <li>Trial of Actemra and Orencia</li> <li>Prescribed by or with a rheumatologist</li> <li>Not also receiving a strong immunosuppressant</li> </ul>	New	7/01/2020
<i>Orencia</i>	abatacept	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>Trial of a disease-modifying anti-rheumatic drug</li> <li>Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR</li> </ul> <p>Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> <li>Trial of leflunomide or methotrexate</li> <li>Trial of Humira</li> </ul> <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara</li> </ul>	Update	7/01/2020
<i>Otezla</i>	apremilast	<p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>No prior drug therapy trials required</li> </ul> <p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>One of the following: greater than 10% body surface area,</li> </ul>	Update	7/01/2020

		<p>palmoplantar involvement, or severe scalp psoriasis</p> <ul style="list-style-type: none"> <li>No prior drug therapy trials required</li> </ul>		
<i>Rinvoq</i>	upadacitinib	<p>Rheumatoid arthritis</p> <ul style="list-style-type: none"> <li>Moderate to severe disease</li> <li>Trial of a disease-modifying anti-rheumatic drug</li> <li>Prescribed by or with a rheumatologist</li> <li>Not also receiving a strong immunosuppressant</li> </ul>	New	7/01/2020
<i>Siliq</i>	brodalumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>No prior oral or topical drug therapy or phototherapy required</li> <li>Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya</li> <li>Trial of Taltz</li> </ul>	Update	7/01/2020
<i>Simponi/Simponi Aria</i>	golimumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>Trial of or is currently taking methotrexate</li> </ul> <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>Active disease</li> <li>No prior therapy required</li> </ul> <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> <li>Active disease</li> <li>Trial of 2 nonsteroidal anti-inflammatory drugs</li> </ul> <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> <li>Corticosteroid dependent OR</li> <li>Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosaliclylate</li> </ul>	Update	7/01/2020
<i>Skyrizi</i>	risankizumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>Moderate to severe disease</li> <li>Prescribed by or with dermatology</li> </ul>	New	7/01/2020
<i>Stelara</i>	ustekinumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>No prior oral or topical drug therapy or phototherapy required</li> <li>No prior biologic therapy required</li> </ul> <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>For 45 mg dose: active disease</li> <li>No prior therapy required</li> <li>For 90 mg dose: active disease with co-existing moderate to severe psoriasis</li> </ul>	Update	7/01/2020

		<ul style="list-style-type: none"> <li>No prior therapy required</li> <li>Weight &gt; 220 pounds</li> </ul> <p>Crohn's Disease</p> <ul style="list-style-type: none"> <li>Trial of at least one tumor necrosis factor (TNF) blocker OR</li> <li>Trial of at least one oral immunomodulator or corticosteroid</li> <li>Intravenous dose: based on weight per FDA-approved doses</li> </ul> <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> <li>Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosalicylate OR</li> <li>Trial of at least one biologic agent (Entyvio or tumor necrosis factor (TNF) blocker)</li> <li>Intravenous dose: based on weight per FDA-approved doses</li> </ul>		
<i>Taltz</i>	ixekizumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>No prior oral or topical drug therapy or phototherapy required</li> <li>Trial of one from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya</li> </ul> <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>Trial of one of the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara</li> </ul> <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> <li>Active disease</li> <li>Trial of 2 nonsteroidal anti-inflammatory drugs</li> <li>Trial of one of the following: Cimzia, Humira, Simponi/Simponi Aria</li> </ul>	Update	7/01/2020
<i>Tremfya</i>	guselkumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> <li>No prior oral or topical drug therapy or phototherapy required</li> </ul>	Update	7/01/2020
<i>Xeljanz/Xeljanz XR</i>	tofacitinib	<p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> <li>Trial of a disease-modifying anti-rheumatic drug</li> <li>Trial of 2 of the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara OR</li> <li>Documented needle phobia</li> </ul> <p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> <li>Trial of a disease-modifying anti-rheumatic drug</li> </ul>	Update	7/01/2020

		<p>Ulcerative Colitis</p> <ul style="list-style-type: none"><li>• Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosalicylate OR</li><li>• Trial of 2 of the following: Humira, infliximab, Simponi, Stelara OR</li><li>• Documented needle phobia</li></ul>		
--	--	---	--	--